People left blind by retinal degeneration have one option: electronic eye implants. Neuroscientists have now developed an alternative: gene therapy that, in tests, restored vision in blind mice. A gene for green opsin delivered via virus gave blind mice enough sight to discern patterns on an iPad at a resolution sufficient for humans to read. Given existing AAV eye therapies already approved, this new therapy could be ready for clinical trials in three years.
